Ageing Population and Medical Tourism

2017 ◽  
Vol 68 (2) ◽  
pp. 207-207
Author(s):  
Thiravud Khuhaprema
Keyword(s):  
Medical Tourism ◽  
Ageing Population

scholarly journals Investment Opportunities in India's Healthcare Sector

2021 ◽  
Author(s):  
Rakesh Sarwal ◽  
Urvashi Prasad ◽  
K. Madan Gopal ◽  
Shoyabahmed Kalal ◽  
Deepyot Kaur ◽  
...  
Keyword(s):  
Health Insurance ◽  
Medical Devices ◽  
Urban Areas ◽  
Medical Tourism ◽  
Healthcare Sector ◽  
Ageing Population ◽  
Annual Growth Rate ◽  
Healthcare Industry ◽  
Indian Government ◽  
The Government

India’s healthcare industry has been growing at a Compound Annual Growth Rate of around 22% since 2016. At this rate, it is expected to reach USD 372 Billion in 2022. Healthcare has become one of the largest sectors of the Indian economy, in terms of both revenue and employment. In 2015, the healthcare sector became the fifth largest employer, employing 4.7 Million people directly. As per estimates by the National Skill Development Corporation (NSDC) healthcare can generate 2.7 Million additional jobs in India between 2017-22 -- over 500,000 new jobs per year. India’s healthcare industry comprises hospitals, medical devices and equipment, health insurance, clinical trials, telemedicine and medical tourism. These market segments are expected to diversify as an ageing population with a growing middle class increasingly favours preventative healthcare. Moreover, the rising proportion of lifestyle diseases caused by high cholesterol, high blood pressure, obesity, poor diet and alcohol consumption in urban areas is boosting demand for specialised care services. In addition to these demographic and epidemiological trends, COVID-19 is likely to catalyse long-term changes in attitudes towards personal health and hygiene, health insurance, fitness and nutrition as well as health monitoring and medical check-ups. The pandemic has also accelerated the adoption of digital technologies, including telemedicine. Further, there is a growing emphasis on and emergence of Public-Private Partnership models in India’s healthcare sector. The country’s relative cost competitiveness and availability of skilled labour are also making it an increasingly favoured destination for Medical Value Travel. On the policy front, the Indian Government is undertaking deep structural and sustained reforms to strengthen the healthcare sector; it has also announced conducive policies for encouraging Foreign Direct Investment (FDI). In fact, India’s FDI regime has been liberalised extensively. Currently, FDI is permitted up to 100% under the automatic route (i.e., the non resident investor or Indian company does not require approval from the Government of India for the investment) in the hospital sector and in the manufacture of medical devices. In the pharmaceutical sector, FDI is permitted up to 100% in greenfield projects and 74% in brownfield projects under the automatic route. India has emerged as one of the fastest-growing emerging economies over the last two decades, receiving large FDI inflows, which have grown from USD 2.5 Billion in 2000-01 to USD 50 Billion in 2019-20. The healthcare sector, in particular, has received heightened interest from investors over the last few years, with the transaction value increasing from USD 94 Million (2011) to USD 1,275 Million (2016) – a jump of over 13.5 times. All of these factors together create several opportunities for investment in India’s healthcare industry.

Nanotheranostic agents for neurodegenerative diseases

2020 ◽  
Vol 4 (6) ◽  
pp. 645-675
Author(s):  
Parasuraman Padmanabhan ◽  
Mathangi Palanivel ◽  
Ajay Kumar ◽  
Domokos Máthé ◽  
George K. Radda ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Neurodegenerative Diseases ◽  
Cell Types ◽  
Specific Cell ◽  
Ageing Population ◽  
Target Tissue ◽  
Therapeutic Approaches ◽  
Surface Receptors ◽  
Theranostic Agents ◽  
Preclinical Animal Models

Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD) and Parkinson's disease (PD), affect the ageing population worldwide and while severely impairing the quality of life of millions, they also cause a massive economic burden to countries with progressively ageing populations. Parallel with the search for biomarkers for early detection and prediction, the pursuit for therapeutic approaches has become growingly intensive in recent years. Various prospective therapeutic approaches have been explored with an emphasis on early prevention and protection, including, but not limited to, gene therapy, stem cell therapy, immunotherapy and radiotherapy. Many pharmacological interventions have proved to be promising novel avenues, but successful applications are often hampered by the poor delivery of the therapeutics across the blood-brain-barrier (BBB). To overcome this challenge, nanoparticle (NP)-mediated drug delivery has been considered as a promising option, as NP-based drug delivery systems can be functionalized to target specific cell surface receptors and to achieve controlled and long-term release of therapeutics to the target tissue. The usefulness of NPs for loading and delivering of drugs has been extensively studied in the context of NDDs, and their biological efficacy has been demonstrated in numerous preclinical animal models. Efforts have also been made towards the development of NPs which can be used for targeting the BBB and various cell types in the brain. The main focus of this review is to briefly discuss the advantages of functionalized NPs as promising theranostic agents for the diagnosis and therapy of NDDs. We also summarize the results of diverse studies that specifically investigated the usage of different NPs for the treatment of NDDs, with a specific emphasis on AD and PD, and the associated pathophysiological changes. Finally, we offer perspectives on the existing challenges of using NPs as theranostic agents and possible futuristic approaches to improve them.

Population Policies in Turkey and Demographic Changes on a Social Map

2016 ◽  
Vol 6 (2) ◽  
pp. 240-266 ◽  
Author(s):  
Mustafa Murat Yucesahin ◽  
Tuğba Adalı ◽  
A Sinan Türkyılmaz
Keyword(s):  
Population Policy ◽  
Developed Countries ◽  
Ageing Population ◽  
Demographic Changes ◽  
Demographic Transitions ◽  
Population Policies ◽  
Demographic Indicators ◽  
The Social ◽  
Working Age ◽  
Low Levels

Compared to its past structure, Turkey is now a country with low levels of fertility and mortality. This junction that Turkey now has reached is associated with a number of risks, such as an ageing population, and a decreasing working-age population. The antinatalist policy era of Turkey was followed by a period of maintenance, yet the recent demographic changes formed the basis of a pronatalist population policy from the government’s view. This study discusses the link between demographic change and population policies in Turkey. It further aims to position Turkey spatially in relation to selected countries that are in various stages of their demographic transitions with different population policies, using a multidimensional scaling approach with data on 25 selected countries from the UN. The analysis is based on a 34-year period, 1975-2009, so as to better demonstrate Turkey’s international position on a social map, past and present. Our findings suggest that Turkey’s position on the social map shifted towards developed countries over time in terms of demographic indicators and population policies. 

Recent Trends in Medical Tourism in India

2011 ◽  
Vol 4 (5) ◽  
pp. 619-621
Author(s):  
K.S. VIJAYANAMBI K.S. VIJAYANAMBI ◽  
◽  
Dr.R.KANNAN Dr.R.KANNAN
Keyword(s):  
Medical Tourism ◽  
Recent Trends

Innovative Strategies For Enhancing the Image of India in Medical Tourism

2011 ◽  
Vol 4 (6) ◽  
pp. 1-3
Author(s):  
P. R. Natarajan P. R. Natarajan ◽  
Keyword(s):  
Medical Tourism ◽  
Innovative Strategies

Medical Tourism in India

2012 ◽  
Vol 3 (1) ◽  
pp. 64-66 ◽  
Author(s):  
Manpreet Kaur ◽  
Keyword(s):  
Medical Tourism

Management of the Asymptomatic Diabetic Patient with Evidence of Ischaemia

2010 ◽  
Vol 6 (1) ◽  
pp. 62
Author(s):  
Dimitrios Bliagos ◽  
Ajay J Kirtane ◽  
Jeffrey W Moses ◽  
◽  
◽  
...  
Keyword(s):  
Coronary Artery ◽  
Medical Therapy ◽  
Artery Bypass ◽  
Coronary Intervention ◽  
Diabetic Patients ◽  
Ageing Population ◽  
Patients With Diabetes ◽  
Risk Patients ◽  
Asymptomatic Diabetic Patient ◽  
Artery Disease

In the US, a total of 23.6 million people have diabetes, representing 7.8% of the population, and the prevalence of diabetes is on the rise due to an increasingly sedentary lifestyle, increasing obesity and an ageing population. Coronary artery disease is the leading cause of death in patients with diabetes, despite a reduction in cardiovascular events over the last 50 years, due in part to better medical therapy. Asymptomatic diabetic patients with evidence of ischaemia on stress testing have higher cardiac mortality; increasing amounts of ischaemia are associated with higher mortality rates. Revascularisation of high-risk patients, or those with significant ischaemia, has the potential to improve outcomes in this patient population. The choice of which revascularisation strategy to choose – either percutaneous coronary intervention (PCI) or coronary artery bypass grafting – should be carefully individualised, and must always be implemented against the background of optimal medical therapy.

MARKETING ISSUES IN MEDICAL TOURISM

2015 ◽  
Vol 2 (5) ◽  
pp. 201-202
Author(s):  
Ki Nam Jin ◽  
Keyword(s):  
Medical Tourism
Sign in / Sign up

Export Citation Format

Share Document